6472 — BORA PHARMACEUTICALS Share Price
Last trade - 00:00- TWD52.99bn
- TWD68.73bn
- TWD19.01bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.55 | ||
| PEG Ratio (f) | 0.83 | ||
| EPS Growth (f) | 21.18% | ||
| Dividend Yield (f) | 2.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.5 | ||
| Price to Tang. Book | 7.92 | ||
| Price to Free Cashflow | 27 | ||
| Price to Sales | 2.71 | ||
| EV to EBITDA | 16.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.06% | ||
| Return on Equity | 13.42% | ||
| Operating Margin | 15.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 4,899.89 | 10,494.47 | 14,200.07 | 17,426.62 | 19,014.17 | 23,248.5 | 29,470.6 | 60.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +269.45 | +82.77 | +108.62 | -13.76 | +58.69 | -43.73 | +75.59 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 12th, 2007
- Public Since
- October 1st, 2014
- No. of Shareholders
- 34,091
- No. of Employees
- 91
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 127,383,059
- Address
- 6F, No.2, Alley 36, Lane 26, Ruiguang Ro, TAIPEI, 114
- Web
- https://www.bora-corp.com/
- Phone
- +886 null227901555
- Contact
- Chin-Chu Wang
- Auditors
- Ernst & Young LLP
Latest News for 6472
Upcoming Events for 6472
Q3 2026 BORA PHARMACEUTICALS CO., LTD. Earnings Release
Similar to 6472
Adimmune
Taiwan Stock Exchange
BRIM BIOTECHNOLOGY
Taiwan Stock Exchange
CALIWAY BIOPHARMACEUTICALS
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech
Taiwan Stock Exchange
FAQ
As of Today at 01:41 UTC, shares in BORA PHARMACEUTICALS are trading at TWD416.00. This share price information is delayed by 15 minutes.
Shares in BORA PHARMACEUTICALS last closed at TWD416.00 and the price had moved by -43.55% over the past 365 days. In terms of relative price strength the BORA PHARMACEUTICALS share price has underperformed the FTSE Developed Asia Pacific Index by -63.97% over the past year.
The overall consensus recommendation for BORA PHARMACEUTICALS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe BORA PHARMACEUTICALS dividend yield is 2.4% based on the trailing twelve month period.
Last year, BORA PHARMACEUTICALS paid a total dividend of TWD10.00, and it currently has a trailing dividend yield of 2.4%. We do not have any data on when BORA PHARMACEUTICALS is to next pay dividends.
We do not have data on when BORA PHARMACEUTICALS is to next pay dividends. The historic dividend yield on BORA PHARMACEUTICALS shares is currently 2.4%.
To buy shares in BORA PHARMACEUTICALS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD416.00, shares in BORA PHARMACEUTICALS had a market capitalisation of TWD52.99bn.
Here are the trading details for BORA PHARMACEUTICALS:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6472
Based on an overall assessment of its quality, value and momentum BORA PHARMACEUTICALS is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BORA PHARMACEUTICALS is TWD537.67. That is 29.25% above the last closing price of TWD416.00.
Analysts covering BORA PHARMACEUTICALS currently have a consensus Earnings Per Share (EPS) forecast of TWD18.89 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BORA PHARMACEUTICALS. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -30.66%.
As of the last closing price of TWD416.00, shares in BORA PHARMACEUTICALS were trading -9.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BORA PHARMACEUTICALS PE ratio based on its reported earnings over the past 12 months is 14.55. The shares last closed at TWD416.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on BORA PHARMACEUTICALS' directors